The NIMH-MATRICS consensus statement on negative symptoms.
作者信息
Kirkpatrick Brian, Fenton Wayne S, Carpenter William T, Marder Stephen R
机构信息
Department of Psychiatry and Health Behavior, Medical College of Georgia, USA.
出版信息
Schizophr Bull. 2006 Apr;32(2):214-9. doi: 10.1093/schbul/sbj053. Epub 2006 Feb 15.
Abstract
摘要
相似文献
1
The NIMH-MATRICS consensus statement on negative symptoms.
Schizophr Bull. 2006 Apr;32(2):214-9. doi: 10.1093/schbul/sbj053. Epub 2006 Feb 15.
2
An industry perspective on the NIMH consensus statement on negative symptoms.
Schizophr Bull. 2006 Apr;32(2):225-30. doi: 10.1093/schbul/sbj056. Epub 2006 Feb 9.
3
The MATRICS consensus cognitive battery: what we know 6 years later.
Am J Psychiatry. 2014 Nov 1;171(11):1151-4. doi: 10.1176/appi.ajp.2014.14070936.
4
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Am J Psychiatry. 2008 Feb;165(2):221-8. doi: 10.1176/appi.ajp.2007.07010089. Epub 2008 Jan 2.
5
Drug initiatives to improve cognitive function.
J Clin Psychiatry. 2006;67 Suppl 9:31-5; discussion 36-42.
6
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
Am J Psychiatry. 2008 Feb;165(2):214-20. doi: 10.1176/appi.ajp.2007.07010043. Epub 2008 Jan 2.
7
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.
8
Cognitive neuroscience and schizophrenia: translational research in need of a translator.
Biol Psychiatry. 2008 Jul 1;64(1):2-3. doi: 10.1016/j.biopsych.2008.04.031.
9
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.
10
Medicine. What are the right targets for psychopharmacology?
Science. 2003 Jan 17;299(5605):350-1. doi: 10.1126/science.1077141.
引用本文的文献
1
Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers.
Mol Psychiatry. 2025 Aug 26. doi: 10.1038/s41380-025-03132-8.
2
Validation of the Romanian version of the brief negative symptom scale in a heterogeneous schizophrenia inpatient sample.
Glob Ment Health (Camb). 2025 Jul 17;12:e85. doi: 10.1017/gmh.2025.10037. eCollection 2025.
3
Targeting Psychotic and Cognitive Dimensions in Clinical High Risk for Psychosis (CHR-P): A Narrative Review.
J Clin Med. 2025 Aug 1;14(15):5432. doi: 10.3390/jcm14155432.
4
Anhedonia and Negative Symptoms in First-Episode Psychosis: A Systematic Review and Meta-Analysis of Prevalence, Mechanisms, and Clinical Implications.
Healthcare (Basel). 2025 Jul 24;13(15):1796. doi: 10.3390/healthcare13151796.
5
The CARE project - study protocol and pilot results from the Polish population.
Front Psychiatry. 2025 Jul 23;16:1643722. doi: 10.3389/fpsyt.2025.1643722. eCollection 2025.
6
Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.
Clin Drug Investig. 2025 Sep;45(9):627-642. doi: 10.1007/s40261-025-01465-4. Epub 2025 Aug 1.
7
Shared Decision-Making in the Management of Schizophrenia: A Systematic Review.
Cureus. 2025 Jun 30;17(6):e87069. doi: 10.7759/cureus.87069. eCollection 2025 Jun.
8
Left amygdala alterations mediate the effects of negative symptoms on social dysfunction in schizophrenia.
Schizophrenia (Heidelb). 2025 Jul 29;11(1):107. doi: 10.1038/s41537-025-00655-5.
9
The moderating role of lifetime social engagement on the relationship between C-reactive protein and negative symptoms among young adults at clinical high risk for psychosis.
Brain Behav Immun. 2025 Jul 27;129:890-897. doi: 10.1016/j.bbi.2025.07.023.
10
Infant rat ultrasonic vocalizations in the neurodevelopmental model of schizophrenia.
Sci Rep. 2025 Jul 28;15(1):27472. doi: 10.1038/s41598-025-08412-5.
本文引用的文献
1
Subdomains within the negative symptoms of schizophrenia: commentary.
Schizophr Bull. 2006 Apr;32(2):246-9. doi: 10.1093/schbul/sbj054. Epub 2006 Feb 21.
2
Treatment of schizophrenia negative symptoms: future prospects.
Schizophr Bull. 2006 Apr;32(2):234-7. doi: 10.1093/schbul/sbj055. Epub 2006 Feb 21.
3
The structure of negative symptoms within schizophrenia: implications for assessment.
Schizophr Bull. 2006 Apr;32(2):238-45. doi: 10.1093/schbul/sbj013. Epub 2005 Oct 27.
4
Anhedonia in schizophrenia: a review of assessment strategies.
Schizophr Bull. 2006 Apr;32(2):259-73. doi: 10.1093/schbul/sbj009. Epub 2005 Oct 12.
5
Negative symptoms and cognitive deficits: what is the nature of their relationship?
Schizophr Bull. 2006 Apr;32(2):250-8. doi: 10.1093/schbul/sbj011. Epub 2005 Oct 12.
6
The factorial structure of the schedule for the deficit syndrome in schizophrenia.
Schizophr Bull. 2006 Apr;32(2):274-8. doi: 10.1093/schbul/sbi064. Epub 2005 Sep 21.
7
Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Schizophr Bull. 2005 Oct;31(4):882-7. doi: 10.1093/schbul/sbi049. Epub 2005 Aug 31.
8
Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.
Schizophr Bull. 2006 Apr;32(2):220-2. doi: 10.1093/schbul/sbi039. Epub 2005 Aug 3.
9
Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis.
Aust N Z J Psychiatry. 2005 Jun;39(6):487-92. doi: 10.1080/j.1440-1614.2005.01608.x.
10
Attributional style and symptoms as predictors of social function in schizophrenia.
J Rehabil Res Dev. 2004 Mar;41(2):225-32. doi: 10.1682/jrrd.2004.02.0225.
Zotero 插件